Investors in QURE Offered Chance to Take Lead in uniQure N.V. Securities Fraud Lawsuit

The Rosen Law Firm is currently taking legal action against uniQure N.V. for alleged securities fraud. This presents an opportunity for investors to lead a lawsuit against the company. The case involves accusations of violating federal securities laws by failing to disclose crucial information about the safety and efficacy of its sole gene therapy, etranacogene dezaparvovec, known as AMT-061.

The law firm’s investigation focuses on whether uniQure and its executives provided misleading or false information to investors about the potential risks associated with their gene therapy product. The lawsuit seeks to hold the company accountable for any misrepresentation that may have impacted investors’ decisions and financial losses.

uniQure shareholders who purchased or acquired company securities between May 13, 2021, and January 6, 2022, are encouraged to participate in the lawsuit. By taking legal action, investors have the opportunity to potentially recover financial losses resulting from alleged securities fraud committed by the company.

Investors interested in participating in the lawsuit against uniQure N.V. can contact The Rosen Law Firm for more information. The law firm is dedicated to investigating and pursuing legal action in cases of securities fraud to protect the rights and interests of investors.

The Rosen Law Firm is a reputable legal entity known for its expertise in handling securities fraud cases. They have a track record of successful litigation against companies accused of misleading investors and violating federal securities laws. With their experience and commitment to justice, the law firm aims to hold uniQure accountable for any alleged misconduct related to their gene therapy product AMT-061.

In conclusion, investors have the opportunity to take legal action against uniQure N.V. for alleged securities fraud involving the company’s gene therapy product. By participating in the lawsuit led by The Rosen Law Firm, investors can seek to recover financial losses resulting from the alleged misrepresentation by uniQure and its executives. Interested investors can contact the law firm for more information on how to participate in the lawsuit and hold uniQure accountable for any misconduct related to their gene therapy product.